MF · holdings as filed 2026-02-28

What's inside BIB?

ProShares Ultra Nasdaq Biotechnology

Holdings

265

positions in the fund

Top 10

52%

of fund assets

Expense ratio

0.95%

net, per year

Fund size

$92M

total net assets

Top 15 holdings

—N/A

16.51%

GILDGILEAD SCIENCES INC

6.48%

VRTXVERTEX PHARMACEUTICALS INC

6.27%

AMGNAMGEN INC

6.15%

—Repurchase Agreement

5.69%

REGNREGENERON PHARMACEUTICALS

4.06%

ALNYALNYLAM PHARMACEUTICALS INC

2.21%

AGPXXINVESCO GVT & AGNCY-INST

1.81%

INSMINSMED INC

1.60%

BIIBBIOGEN INC

1.42%

ARGXARGENX SE - ADR

1.12%

UTHRUNITED THERAPEUTICS CORP

1.09%

MRNAMODERNA INC

1.05%

ILMNILLUMINA INC

1.03%

ROIVROIVANT SCIENCES LTD

1.01%

Sectors

1Health Care

63%

2Unclassified

26%

3Industrials

4Information Technology

Geography

1United States

62%

2Unclassified

24%

3United Kingdom

4Bermuda

5Ireland

6Germany

7Canada

8Netherlands

Hold BIB alongside other funds? See your combined true holdings, overlap, and blended fees — free, no signup.

Unwrap your portfolio →

Data source: official SEC Form N-PORT filings (as of 2026-02-28); expense ratio from SEC prospectus (risk/return) filings. Fund holdings are disclosed quarterly and may reflect a 60-day reporting delay.
Informational and educational only — not investment advice.